Parasympathomimetics

Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here.

Also Known As:

Networked: 48 relevant articles (3 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Angioi-Duprez, K: 1 article (05/2022)
2.	Bursztejn, A C: 1 article (05/2022)
3.	Gillet, P: 1 article (05/2022)
4.	Patchinsky, A: 1 article (05/2022)
5.	Petitpain, N: 1 article (05/2022)
6.	Schmutz, J L: 1 article (05/2022)
7.	Abo-Elseoud, Mohammed: 1 article (02/2022)
8.	Artopoulou, Eleni: 1 article (02/2022)
9.	Gerakaris, Andreas: 1 article (02/2022)
10.	Koniari, Ioanna: 1 article (02/2022)

Related Diseases

1.	Underactive Urinary Bladder 01/01/2022 - "Overall, it is not possible to draw clear evidence-based conclusions from the current literature, presenting the use of parasympathomimetics for treating underactive bladder as a key area that requires future well-controlled clinical trials." 01/01/2022 - "The aim of this review was to assess the effectiveness, both benefits and harms, of using parasympathomimetics for the treatment of underactive bladder. " 01/01/2022 - "The effectiveness of parasympathomimetics for treating underactive bladder: A systematic review and meta-analysis." 04/01/2007 - "Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based?" 01/01/2022 - "Biological rationale suggests that parasympathomimetics (cholinergic receptor stimulating agents) could be beneficial for patients with underactive bladder. "
2.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/01/2009 - "Currently, no clinical trial supporting the use of parasympathomimetic drugs in those with poor voiding and longstanding symptomatic benign prostatic hyperplasia exists in the literature; however, experimental studies present promising results."
3.	Myasthenia Gravis 06/01/2012 - "Parasympathomimetics, immunosuppression and plasmapheresis have considerably improved management and prognosis of myasthenia gravis. "
4.	Glaucoma 01/01/2013 - "Medical treatment of glaucoma includes topical beta-blockers, alpha-2 agonists, prostaglandins, parasympathomimetics and CAIs. " 03/01/2014 - "Other glaucoma medications (beta blockers, carbonic anhydrase inhibitors, parasympathomimetics, and prostaglandin analogues) are classified as category C medications with uncertain safety from the lack of human studies and reported adverse effects in animal studies. " 03/01/2011 - "Prostaglandin analogs, β-blockers, α-agonists, carbonic anhydrase inhibitors and parasympathomimetics are available in our glaucoma armamentarium and are reviewed. " 05/11/2009 - "Parasympathomimetics, adrenergic antagonists, plus eventually adrenergic agonists, are commonly used for the reduction of IOP and therefore for treatment of glaucoma. " 10/01/1989 - "Four major classes of drugs are currently used to treat glaucoma: carbonic anhydrase inhibitors, beta adrenergic blockers, parasympathomimetics, and sympathomimetics. "
5.	Ulcer 01/01/1947 - "Studies of gastric motility on ulcer patients before and after vagotomy; effect of parasympathomimetic drugs."

Related Drugs and Biologics

1.	Cholinergic Receptors
2.	Carbonic Anhydrase Inhibitors
3.	Synthetic Prostaglandins (Prostaglandin Analogues)
4.	Muscarinic Agonists
5.	Sympathomimetics (Sympathomimetic Amines)
6.	Adrenergic Receptors (Adrenergic Receptor)
7.	Pilocarpine (Ocusert)
8.	Oxotremorine
9.	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)
10.	Cholinergic Agents (Cholinergics)

Related Therapies and Procedures

1.	Plasmapheresis
2.	Vagotomy
3.	Therapeutics
4.	Radiotherapy
5.	Immunotherapy